KR101528449B1 - A composition for improving skin conditions containing tetrandrine - Google Patents

Abstract

The present invention relates to a composition containing tetrandrine for improving leukoderma. According to the invention, the composition contains tetrandrine as an active ingredient and has effects of generating melanin and increasing tyrosinase activity thereby having an advantage of improving leukoderma. In addition, the tetrandrine has no cellular cytotoxicity and skin side effects and thus can be used safely as cosmetic compositions, pharmaceutical compositions, and food compositions.

Description

TECHNICAL FIELD [0001] The present invention relates to a composition for improving skin condition including tetranidine,

TECHNICAL FIELD The present invention relates to a composition for improving skin condition comprising tetrandrine, and more particularly to a cosmetic composition, a pharmaceutical composition and a food composition for improving hypochromatosis comprising tetranidine as an active ingredient will be.

The skin color of a person is determined by the concentration and distribution of melanin in the skin. The melanin pigment produced in the melanocytes of the skin is a phenolic polymer substance having a complex form of a black pigment and a protein, and plays an important role in blocking skin damage caused by ultraviolet rays. In melanin biosynthesis, the action of tyrosinase, which is present in melanocytes, is the most important. Such tyrosinase is a kind of tyrosine, which is a kind of amino acid, is converted to the intermediate products of melanin polymer production (DOPA) and dopaquinone (dopaquinone), it plays a key role in the skin blackening process. Melanin absorbs ultraviolet light energy in the sunlight to protect cells deep in the skin from damage by ultraviolet rays. However, abnormal production of melanin causes abnormal skin pigmentation such as spots, freckles, pigmentation, etc. , And in contrast, less production leads to the development of melanin such as vitiligo, decolorization nodule, pseudoleucoderma atopicum, Tinea versicolor, scleroderma, allergy, post-inflammatory decolorization, idiopathic hypoglycemia, Leukoderma (Bolognia and Pawelek, J Am Acad Dermatol (1988) 19: 217-255; Pinto and Bolognia, Pediatr Clin North Am (1991) 38: 991-1017). Among the melanin hypochromatosis diseases, vitiligo is a disease in which melanocytes are destroyed and the other disease is a disease caused by a decrease in the amount of melanin produced in melanocytes. The hypoxia treatment methods reported so far include photochemical methods using photosensitizers such as psoralen, surgical methods such as surgery, methods of increasing melanin production by increasing the activity of melanocytes, methods of increasing melanin cells from oxidative stress And how to protect them.

Accordingly, the inventors of the present invention have found that tetranurin induces melanin production and exhibits hypotonic hypochromatosis as a result of studying for a substance having low hypochromatosis improvement effect and low human side effect as described above. Thus completing the present invention.

Accordingly, a technical problem to be solved by the present invention is to provide a substance having a skin hypocholality improving effect and excellent human safety.

In order to solve the above-mentioned technical problems, the present invention provides a composition for improving skin hypochromatosis, which comprises tetranidine as an active ingredient.

Preferably, the composition comprising tetranurine in the present invention may be a cosmetic composition, a pharmaceutical composition or a food composition.

Tetrandrin , an active ingredient of the composition of the present invention, is a component of the alkaloid species of the root extract of Stephania tetrandria S. Moore or Stephania japonica Miers with a new sand vine, Lt; / RTI >

Tetrandrine is known to have therapeutic efficacy for metabolic diseases such as diabetes, hyperlipidemia, fatty liver, arteriosclerosis, hypertension, cardiovascular disease. Tetrandrin is known to be able to treat obesity and diabetes by acting as a decisive factor in increasing the secretion of adiponectin protein and causing insulin resistance.

In the present invention, the tetrandrin compound is applied to the leaves of Stephania tetrandria S. Moore ) or Stephania japonica Miers , or may be chemically synthesized and used or commercially available, and there is no particular limitation.

The composition of the present invention may contain 0.00001 to 50% by weight, more preferably 0.0001 to 30% by weight, and most preferably 0.0001 to 10% by weight, based on the total weight of the composition. When the amount of the tetranidine is less than 0.00001% by weight, the effect of improving skin hypochlorite is insignificant. When the content is more than 50% by weight, the increase of the effect of the content is not proportionally increased, Is not secured.

According to one embodiment of the present invention, there is provided a composition for improving skin hypochromatosis comprising tetranurine as an active ingredient. The composition of the present invention protects skin cells from ultraviolet rays while having little cytotoxicity. In particular, it activates melanocytes that protect skin from ultraviolet rays to exert skin protection effect. Skin soothing effect, skin blackening inducing effect, skin cancer prevention effect).

As used herein, the term " hypochromogenesis "refers to a melanogenesis action that improves skin troubles such as vitiligo and white hair caused by abnormal melanin cell or melanin pigment synthesis function and reduced melanin production.

In the composition for improving skin hypochromatosis according to the present invention, tetranidine increases melanin production of human-derived melanocytes, has high stability, and has little side effects such as skin irritation induction.

In the composition of the present invention, besides tetranidine as an active ingredient, a component having a skin hypocholality improving effect may be further added, and glycyrrhizin may be mixed with tetrandrin.

The amount of the glycyrrhizin added may be 0.00001 to 50 wt%, more preferably 0.0001 to 30 wt%, and most preferably 0.0001 to 10 wt%, based on the total weight of the composition.

By adding glycerin together with tetranidine to the composition of the present invention, it is possible to obtain a synergistic effect which is significantly improved in improving skin hypochromatosis.

Preferably, according to one embodiment of the present invention, there is provided a composition for improving hypochromatosis, which comprises tetranin and glycyrrhizin as an active ingredient.

The composition of the present invention may be a cosmetic composition, a pharmaceutical composition or a food composition.

The cosmetic composition according to one embodiment of the present invention may contain, in addition to tetranidine as an active ingredient, conventional additives such as antioxidants, stabilizers, solubilizers, vitamins, pigments, and perfumes, The carrier may be further added.

The cosmetic composition of the present invention can be prepared into any of the formulations conventionally produced in the art and can be used as a solution, a suspension, an emulsion, a paste, a gel, a cream, a lotion, a powder, a soap, , Oil, powder foundation, emulsion foundation, wax foundation and spray, but is not limited thereto. More specifically, it can be prepared as a nutritional cream, a convergent lotion, a soft lotion, a lotion, an essence, a nutritional gel or a massage cream.

When the formulation of the present invention is a paste, a cream or a gel, an animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide .

When the formulation of the present invention is a powder or a spray, tosse, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In the case of a spray, in particular, chlorofluorohydrocarbons, propane / Propane or dimethyl ether.

When the formulation of the present invention is a solution or emulsion, a solvent, a solubilizing agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.

In the case where the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tragacanth.

When the formulation of the present invention is an interfacial active agent-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters.

A pharmaceutical composition according to one embodiment of the present invention comprises a pharmaceutically acceptable carrier other than tetranurine. The pharmaceutically acceptable carrier to be contained in the pharmaceutical composition of the present invention is one usually used at the time of formulation, and includes lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, But are not limited to, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrups, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. It is not. The pharmaceutical composition of the present invention may further contain a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, etc., in addition to the above components. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington ' s Pharmaceutical Sciences (19th ed., 1995).

The pharmaceutical composition of the present invention can be administered orally or parenterally, and is preferably applied by parenteral administration, more preferably topical application by application.

A suitable dosage of the pharmaceutical composition of the present invention may vary depending on such factors as the formulation method, administration method, age, body weight, sex, pathological condition, food, administration time, route of administration, excretion rate, . The dosage of the pharmaceutical composition of the present invention is in the range of 0.001-100 mg / kg on an adult basis. When the composition is an external preparation, it is preferably applied in an amount of 1.0 to 3.0 ml on an adult basis once to five times a day, and continued for 1 month or more. However, the dose is not intended to limit the scope of the present invention.

The pharmaceutical composition of the present invention may be prepared in unit dosage form by formulating it using a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by a person having ordinary skill in the art, Into the container. The formulations may be in the form of solutions, suspensions, syrups or emulsions in an oil or aqueous medium, or in the form of excipients, powders, powders, granules, tablets or capsules, and may additionally contain dispersing or stabilizing agents.

In addition, the food composition according to one embodiment of the present invention may contain not only tetranurin as an active ingredient but also ingredients normally added in the manufacture of food such as protein, carbohydrate, fat, nutrients, May be further included.

Examples of such carbohydrates are monosaccharides, such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And polysaccharides such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavorings such as tau martin and stevia extract (e.g., rebaudioside A and glycyrrhizin) and synthetic flavorings (saccharine, aspartame, etc.) can be used as flavorings.

For example, when the food composition of the present invention is prepared as a drink, it may further contain citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, juice, mulberry extract, jujube extract, licorice extract, .

On the other hand, Tetrandrin of the present invention is harmless to the human body, has little toxicity and side effects, and can be safely used for a long period of use. In particular, it can be safely applied to cosmetic, pharmaceutical and food compositions as described above.

As described above, the composition containing the tetranurine of the present invention as an active ingredient has an effect of increasing the melanin production and tyrosinase activity, thereby improving the skin hypochromatosis. Tetrandrin also has no cytotoxic and skin side effects and can be used safely in cosmetic, pharmaceutical and food compositions.

BRIEF DESCRIPTION OF THE DRAWINGS The accompanying drawings, which are incorporated in and constitute a part of the specification, illustrate exemplary embodiments of the invention and, together with the description of the invention, It should not be construed as limited.
FIG. 1 is a graph showing the effect of tetranurine on melanin production observed in human epidermal melanocytes. FIG.
Fig. 2 is a graph showing the synergistic effect of melanin production in human melanoma-forming cells when mixed with tetranidine and glycyrrhizin.
FIG. 3 is a graph showing the effect of increasing the expression of genes involved in melanin production by tetranidine in mouse pigment cells (B16 melanoma cells).

Hereinafter, embodiments of the present invention will be described in detail to facilitate understanding of the present invention. However, the embodiments according to the present invention can be modified into various other forms, and the scope of the present invention should not be construed as being limited to the following embodiments. Embodiments of the invention are provided to more fully describe the present invention to those skilled in the art.

Example 1 Measurement of Increase of Melanin Production of Human Epidermal Melanin-forming Cell by Tetradrin

Human epidermal melanocytes were used to measure the increase of melanin production by tetrandrine.

Human epidermal melanocytes (obtained from Cascade Biologics) were cultured in medium 254 medium (obtained from Cascade Biologics) containing human melanocyte growth supplements. After inoculation the human epidermal melanin forming cells 6-well plate to 1 X 10 ⁵ pieces per well were cultured under 5% CO _2, 37 ℃ until the cell is attached to at least about 80% of the well bottom.

After the culture, the medium was removed, the sample was diluted, and the medium was treated with 5% CO _{2 at} 37 ° C for 5 days while changing the medium once a day. The dilution concentration range of tetranidine (available from Sigma-Aldrich) was set to 1 uM, 10 uM, and 50 uM without cytotoxicity. After the treatment, the medium was removed, washed with PBS (phosphatized buffer saline), and treated with trypsin to recover the cells. The recovered cells were counted using a hematocytometer, centrifuged at 5,000 ~ 10,000 rpm for 10 minutes, and the supernatant was removed to obtain cells.

The obtained cells were dried at 60 DEG C, and 100 mu l of 1 M sodium hydroxide solution containing 10% DMSO was added thereto to obtain intracellular melanin solution in a 60 DEG C thermostatic chamber. The obtained melanin solution was measured for absorbance at 490 nm with a microplate reader to determine the amount of melanin per cell constant.

As a comparative group, 10 μM of Folscholin was used, and a blank group was used as a control group (-). The results are shown in Fig.

As shown in FIG. 1, it was found that the amount of melanin due to tetranidine treatment in the human epidermal melanin-forming cells was increased in a concentration-dependent manner. From this, it was confirmed that tetrandrin showed a blackening effect on human cells.

Example 2 Measurement of Increase in Intracellular Tyrosinase Activity by Tetradrin

Human melanocytes were used to measure the effect of tetrandrine on tyrosinase activity.

Human epidermal melanocytes (obtained from Cascade Biologics) were cultured in medium 254 medium (obtained from Cascade Biologics) containing human melanocyte growth supplements. After inoculation the human epidermal melanin forming cells 6-well plate to 1 X 10 ⁵ pieces per well were cultured under 5% CO _2, 37 ℃ until the cell is attached to at least about 80% of the well bottom.

After the culture, the medium was removed, the sample was diluted, and the medium was treated with 5% CO _{2 at} 37 ° C for 5 days while changing the medium once a day. The dilution concentration range of tetranidine (available from Sigma-Aldrich) was set to 1 uM, 10 uM, and 50 uM without cytotoxicity. After the treatment, the medium was removed, washed with PBS, and treated with trypsin to recover the cells. The recovered cells were counted using a hematocytometer, centrifuged at 5,000 ~ 10,000 rpm for 10 minutes, and the supernatant was removed to obtain cells. The cells were pulverized using a lysis buffer and centrifuged at 12,000 rpm for 10 minutes to collect the supernatant. 40 μl of the enzyme solution was added, and 100 μl of a substrate L-dopa dissolved at 2 mg / ml was added. After incubation at 37 ° C for 1 hour, the absorbance was measured at 492 nm using a microplate reader to calculate tyrosinase activity. The activity of tyrosinase was calculated as a percentage of the absorbance of the control group. As a comparative group, 10 μM of phoscholine was used, and the results are shown in Table 1 below.

sample Treatment concentration Increase in intracellular tyrosinase activity (%) forskolin 10 uM 75.01 Tetrandrin 1 uM 14.22 Tetrandrin 10 uM 73.12 Tetrandrin 50 uM 89.18

As shown in Table 1, the group treated with 50 uM of tetranidine showed a higher rate of increase of intracellular tyrosinase activity than the group treated with phoscholin. It was also found that the degree of increase in tyrosinase activity of tetralin was dependent on the concentration.

<Example 3> Cytotoxicity measurement of tetranidine

Newborn human epidermal melanocyte-forming cells (obtained from Cascade Biologics) were cultured in Medium 254 medium containing human melanin-forming cell growth supplements. Human epidermal melanin-forming cells were inoculated in a 6-well plate at 1 × 10 ⁵ cells per well. Cells were incubated at 37 ° C in 5% CO ₂ until the cells were attached to the wells at least 80%.

After the culture, the medium was removed, and tetranurine was treated in a medium diluted to 1 uM, 10 uM and 50 uM, and cultured at 37 ° C in 5% CO _{2 for} 2 days. The cytotoxic effect was measured by MTT (3- (4,5-dimetylthiazol-2-yl) 2,5-diphenyltetrazolium bromide) assay. MTT is a pale yellow substrate, cleared by respiratory chain enzymes in the mitochondria of living cells and producing a dark blue formazan. Since the reaction does not occur in dead cells, the amount of this formazan is used to measure the number of living cells. The results are shown in Table 2 below.

sample Treatment concentration Cell viability (% of control) forskolin 10 uM 100 ± 6.5 Tetrandrin 1 uM 101.2 ± 2.2 Tetrandrin 10 uM 100.04 1.8 Tetrandrin 50 uM 101.02 ± 1.2

As shown in Table 2, it was confirmed that tetranidine did not show cytotoxicity in all concentration groups.

Example 4 Measurement of synergistic effect on melanin production of human epidermal melanin-forming cells by mixing tetranidine and glycyrrhizin (Glycyrrhizin)

Human epidermal melanocyte-forming cells were used to measure the synergistic effect of melanin production on the increase of melanin production by mixing with tetralin and glycyrrhizin (Sigma Aldrich).

The newborn-derived human epidermal melanocyte-forming cells were cultured in medium 254 medium containing human melanin-forming cell growth promoting agent. After inoculation the human epidermal melanin forming cells 6-well plate to 1 X 10 ⁵ pieces per well were cultured under 5% CO _2, 37 ℃ until the cell is attached to at least about 80% of the well bottom.

After the culture, the medium was removed, the sample was diluted, and the medium was treated with 5% CO _{2 at} 37 ° C for 5 days while changing the medium once a day. The treatment concentration was set to 5 uM of tetrandrin, 10 uM of tetralin, 5 uM of glycyrrhizin, 10 uM of glycyrrhizin, 5 uM of tetranidine, and 5 uM of glycyrrhizin. After the treatment, the medium was removed, washed with PBS, and treated with trypsin to recover the cells. The recovered cells were counted using a hematocytometer, centrifuged at 5,000 ~ 10,000 rpm for 10 minutes, and the supernatant was removed to obtain cells. The cells were dried at 60 ° C., and 100 μl of a 1 M sodium hydroxide solution containing 10% DMSO was added thereto to obtain intracellular melanin in a 60 ° C. thermostatic chamber. The absorbance of this solution was measured at 490 nm using a microplate reader, and the amount of melanin per cell constant was determined. 10 μM of Folscholine was used as a comparative group, and blank test group was used as a control (-). The results are shown in Fig.

As shown in FIG. 2, melanin levels in human epidermal melanin-forming cells were significantly increased in the group treated with tetranidine and glycyrrhizin, compared with the group treated with tetranin and glycyrrhizin alone, respectively. From these results, it was confirmed that mixing of tetrandrin and glycyrrhin exhibits mutually synergistic blackening effect.

&Lt; Example 5 > Measurement of effect of tetranidine on the expression of genes involved in melanin production

B16 melanoma cells were used to measure the effect of tetralin on genes involved in melanogenesis.

In this experiment, murine melanoma (B-16 F10) cells were inoculated with DMEM medium containing 10% FBS (fetal bovine serum) at a dose of 1 ㅧ 10 ⁵ per well in a 6-well plate, The cells were cultured until 80% or more of them were adhered. After the culture, the medium was removed, the sample was treated with a medium diluted to an appropriate concentration, and cultured at 37 ° C in 5% CO _{2 for} 2 days. The concentration of tetralin was determined to be 100 uM without cytotoxicity.

Subsequently, the cells from which the medium was removed were washed with PBS and treated with trypsin to recover the cells. The recovered cells were counted using a hematocytometer. Cells were divided into 2-mL tubes in equal numbers, centrifuged at 5,000 to 10,000 rpm for 10 minutes, and the supernatant was removed to obtain pellets. Total RNA was isolated from this cell pellet using TRIzol reagent (Carlsbad, CA, USA, Invitrogen) and cDNA was synthesized using random primers and Moloney murine leukemia virus reverse transcriptase (Carlsbad, CA, USA, Invitrogen). Real-time PCR analysis was performed using an ABI7900HT machine (Applied Biosystems), where Taqman analysis was used. Using the Taqman probe of each gene, expression of genes was measured by real-time PCR assay. (Taqman), MITF, Tyrosinase, TRP1, TRP2 and GAPDH (PCR conditions: 50 C for 2 min, 60 C for 30 min, 95 C for 5 min and PCR cycle: 45 times) et al., 2003, J Lipid Res, 44, 968-977).

The results are shown in Fig. As shown in FIG. 3, it was confirmed that tetranin increased the expression of tyrosinase, MITF, TRP1 and TRP2 genes involved in melanin biosynthesis.

From the above test results, it was confirmed that tetranurine is effective for melanogenesis.

As described above, the composition containing the tetranurine of the present invention as an active ingredient has an effect of increasing the melanin production and tyrosinase activity, thereby improving the skin hypochromatosis. Tetrandrin also has no cytotoxic and skin side effects and can be used safely in cosmetic, pharmaceutical and food compositions.

Claims (6)

A cosmetic composition for improving skin hypochromatosis comprising tetranurine as an active ingredient. A pharmaceutical composition for the treatment or prevention of hypothenopathy which comprises tetranidine as an active ingredient. A food composition for improving skin hypochromatosis comprising tetranidine as an active ingredient. The method according to claim 1,
Wherein the composition comprises the tetranurine in an amount of 0.00001 to 50% by weight based on the total weight of the composition. The method according to claim 1,
Wherein the composition further comprises glycyrrhizin. 6. The method of claim 5,
Characterized in that said glycyrrhizin is present in an amount of from 0.00001 to 50% by weight, based on the total weight of the composition.

Images